Van ECK Associates Corp Has $13.64 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Van ECK Associates Corp lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 57,679 shares of the medical research company’s stock after selling 5,418 shares during the period. Van ECK Associates Corp owned 0.11% of Charles River Laboratories International worth $13,635,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. VisionPoint Advisory Group LLC raised its stake in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after acquiring an additional 74 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Charles River Laboratories International in the third quarter valued at approximately $37,000. Operose Advisors LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth approximately $42,000. Venturi Wealth Management LLC lifted its holdings in Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after buying an additional 112 shares in the last quarter. Finally, Provence Wealth Management Group bought a new position in Charles River Laboratories International in the 3rd quarter valued at $57,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Up 1.6 %

NYSE:CRL opened at $232.69 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The stock has a 50-day moving average price of $253.02 and a two-hundred day moving average price of $223.58. The stock has a market cap of $11.99 billion, a price-to-earnings ratio of 25.26, a PEG ratio of 1.82 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. Charles River Laboratories International’s quarterly revenue was down 7.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.98 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock valued at $3,693,663 over the last quarter. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CRL. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Citigroup boosted their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Evercore ISI raised their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Robert W. Baird boosted their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).